Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Inflammatory Disease Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for CXCR6/CD186 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CXCR6 Extracellular Loop (ECL) / N-terminal Fragment Recombinant Protein High purity (>95%), Endotoxin controlled. Sequence Verified. |
View CXCR6 Products |
| Gene Delivery | CXCR6 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. Conformation-preserved GPCR screening. |
View CXCR6 Products |
| Benchmark Ab | Anti-CXCR6 Recombinant Biosimilar Antibody Recombinant positive control for flow cytometry and binding assays. |
View CXCR6 Products |
| Validator | CXCR6 siRNA Set For knockdown verification in target-validation assays. |
View CXCR6 Products |
| Related Target A | CXCL16 The cognate chemokine ligand for CXCR6, crucial for chemotaxis and binding assays. |
View CXCL16 Products |
| Related Target B | CXCR3 Synergistic chemokine receptor involved in T-cell trafficking and tumor homing. |
View CXCR3 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Multi-pass transmembrane conformation preservation | Lentivirus for Stable Cell Line generation ensures native 7-TM GPCR folding. |
| Cross-species reactivity validation (Cyno/Mouse) | Human, Mouse, and Cynomolgus ortholog sequences strictly verified. |
| Lack of functional controls for chemotaxis | Bioactive CXCL16 ligand and sequence-verified positive control antibodies available. |
| Off-target screening against GPCR family | Homolog panel reagents and cell lines verified by sequence and expression profiles. |
Live CXCR6/CD186 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of the CXCR6/CD186 axis is carving out a highly specialized niche in both oncology and immunology. As a G-protein coupled receptor (GPCR) predominantly expressed on CXCR6+ CD8+ T cells, NKT cells, and tumor-infiltrating lymphocytes (TILs), CXCR6 regulates trafficking to CXCL16-expressing tissues, notably the liver and specific tumor microenvironments.
The race for CXCR6 therapeutics is intensifying, with major players shifting focus from traditional mAbs to cell therapies and small molecule antagonists. In oncology, the next wave of R&D is targeting CXCR6 overexpression in CAR-T and TCR-T cell therapies to enhance homing and infiltration into solid tumors, particularly hepatocellular carcinoma (HCC) and ovarian cancers. Conversely, in autoimmune and inflammatory diseases—such as NASH, liver fibrosis, and rheumatoid arthritis—blocking the CXCR6/CXCL16 axis with small molecules or monoclonal antibodies represents a major therapeutic avenue to prevent pathogenic immune cell recruitment.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| CAR-T / Cell Therapy | Academic Institutes, Biotech Startups | Solid Tumors (HCC, Ovarian Cancer) | Stable cell lines expressing CXCR6/CXCL16 (Need Lentiviral systems) |
| Monoclonal Antibody (Antagonist) | Biopharma Corporates | NASH, Liver Fibrosis, Autoimmune | Epitope mapping & ligand blocking assays (Need native GPCR conformation) |
| Small Molecule Inhibitor | Inception Therapeutics, GPCR Specialists | Chronic Inflammatory Diseases | High-throughput Calcium Flux & Chemotaxis assays (Need stable reporter lines) |